<DOC>
	<DOCNO>NCT02893111</DOCNO>
	<brief_summary>Neuromyelitis Optica Spectrum Disorders ( NMOSD ) characterize pathogenic anti-AQP4 antibody , produce specific plasma cell . The patient responsive rituximab treatment may due presence short-lived long-lived plasma cell . Previous study confirm proteasome inhibitor bortezomib ( Velcade® , approve therapy multiple myeloma ) eliminate plasmablast plasma cell activation terminal unfold protein response . Treatment bortezomib may help deplete plasma cell produce auto-antibodies . Therefore , rationale use bortezomib NMOSD bortezomib may help eliminate autoreactive plasma cell reduce anti-AQP4 antibody titer . It note bortezomib may protect astrocyte NFκB-dependent inflammatory damage early event NMOSD pathogenesis . The purpose study determine drug bortezomib contribute reduce average relapse rate ( ARRs ) alleviate neurological disability NMOSD patient .</brief_summary>
	<brief_title>Efficacy Safety Bortezomib add-on Treatment Relapsing Neuromyelitis Optica Spectrum Disorder</brief_title>
	<detailed_description>It show scientific study antibody marker specific neuromyelitis optica spectrum disorder ( NMOSD ) , know AQP4-IgG , cause inflammation brain tissue activate NF-κB pathway . Bortezomib already show effective systemic lupus erythematosus ( SLE ) . The overall objective ass efficacy safety bortezomib add-on therapy oral steroid , azathioprine others treatment relapse NMOSD , reduce average relapsing rate ( ARR ) effectively . The primary ( important ) objective study determine : Whether bortezomib reduces relapse frequency patient relapse NMO . The number attack one year treatment period compare number attack occur prior initiation bortezomib treatment . The secondary objective determine : The safety profile bortezomib patient NMO . Whether bortezomib maintain improves walk , visual function quality life measure variety establish disability scale . We also assess severity individual attack degree recovery . Depending preliminary investigation may evaluate patient cerebrospinal fluid laboratory see effective eculizumab get cerebrospinal fluid blood stream , see drug revers biological effect NMO-IgG antibody .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>Age ≥18 year Diagnosis NMOSD , define 2015 criterion OR NMOSD seropositive spectrum disorder ( Recurrent ON longitudinally extensive transverse myelitis ( LETM ) ) . All patient must NMOIgG seropositive . Clinical evidence least 2 relapse last 6 month 3 relapse last 12 month ( least 1 relapse occur precede 6 month ) The B cell count must normal ( 520 % total lymphocyte ) subject administration bortezomib Provision write informed consent participate study Corrected visual acuity 20/100 good least one eye ; otherwise , last attack myelitis attack myelitis outcomes Ambulatory ( without walker ) ; otherwise , last attack optic neuritis attack optic neuritis outcomes Current evidence know history clinically significant infection ( HSV , VZV , CMV , EBV , HIV , Hepatitis viruses , Syphilis , etc ) Pregnant , breastfeeding , childbearing potential course study Patients participate clinical therapeutic study participate experimental treatment study within 30 day screen Patients history splenectomy , potential increase risk develop meningococcal infection Participation another interventional trial within last 3 month Preexistent sensory motor polyneuropathy ≥ degree 2 ( NCI CTC AE criterion ) , within 14 day screen Heart kidney insufficiency Tumor disease currently within last 5 year Clinically relevant liver , kidney bone marrow function disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>neuromyelitis optica spectrum disorder</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
	<keyword>Proteasome inhibitor</keyword>
</DOC>